Fundz

Aavanti Bio, Inc. reported raising $41.8 Million in an initial SEC Form D filing, from an offering of $107 Million

PRIVATENov 19, 2020$41.8M of $106.9M raised

Amount Raised

$41.8 Million

$41.8 Million sold, per SEC Form D (first sale Nov 19, 2020)

Round Type

Venture

GainesvilleBiotechnologyHealth CareGeneticsTherapeutics

Who else raised in Genetics and Therapeutics around the same time

Companies in the same sectors as AavantiBio, Inc. that raised within 45 days of this round, from Fundz verified event records.

  • Elevation Oncology raised $65M on November 18, 2020.
  • Solid Biosciences raised $40M on October 26, 2020.
  • Neurogene raised $69M on December 29, 2020.
  • 23andMe raised $82M on December 28, 2020.
  • Alpha Cognition raised $1.5M (Seed) on December 28, 2020.
  • Definium Therapeutics raised $78K (Seed) on December 22, 2020.

Who to call at AavantiBio, Inc., and when

A new round usually means AavantiBio, Inc. is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day AavantiBio, Inc. raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at AavantiBio, Inc., from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at AavantiBio, Inc.. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

AavantiBio, Inc.

Location

First Street Riverview Ii

Gainesville, Florida, United States

About

AavantiBio is a gene therapy company focused on advancing innovative gene therapies in areas of high unmet medical need, including a lead program in Friedreich’s ataxia, a rare inherited genetic disease that causes cardiac and central nervous system dysfunction, and programs in dilated or hypertrophic cardiomyopathies, and a next generation cardiac capsid library. The company benefits from strategic partnerships with the University of Florida’s Powell Gene Therapy Center and the MDA Care Center at UF Health where AavantiBio’s co-founders and renowned gene therapy researchers Barry Byrne, M.D., Ph.D. and Manuela Corti, P.T., Ph.D. maintain their research and clinical practices. Learn more at www.aavantibio.com.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment AavantiBio, Inc. raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Predictive Intelligence
Strategic

ML-powered predictions for AavantiBio, Inc.'s next move

See what Strategic adds

AavantiBio, Inc. raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.